Furthermore, a subset of IBD patients have elevated IL-22 expression levels (as also shown in our IBD cohort), which were reduced following anti-IL23 treatment resulting in high rates of clinical responses and remission, further suggesting that IL-22 is rather detrimental than protective in IBD [19]. This evidence concerns the gene IL22 and inflammatory bowel disease.